PPD forms new unit with Evidera, MARO teams

By Melissa Fassbender contact

- Last updated on GMT

PPD acquired Evidera last year. (Image: iStock/phive2015)
PPD acquired Evidera last year. (Image: iStock/phive2015)
Pharmaceutical Product Development, LLC (PPD) has combined its medical affairs research operations (MARO) team and Evidera to create a dedicated real-world research and market access unit.

"This new, dedicated real-world research and market access unit will combine ​Evidera’s multidisciplinary scientific and consulting expertise to design studies, analyze findings and communicate outcomes, with PPD’s global operational infrastructure to manage and implement both interventional and observational studies​," Randy Buckwalter, a PPD spokesperson told Outsourcing-Pharma.com.

"The new unit will enable us to help our clients seamlessly integrate and align regulatory and post-approval research efforts, creating a smooth transition from Phase III to Phase IIIb/IV and real-world research, and improving their ability to meet the evidence demands of both regulators and payers​," he added.

PPD completed its acquisition of the evidence-based solutions provider, Evidera, in September of last year.

Jon Williams, who has served as the president and CEO of Evidera since 2013, told us at the time​ that both companies were committed to a seamless integration. 

The new dedicated unit will provide customers with various solutions, including modeling and simulation, interventional studies, observational studies, health economics, outcomes research, market access, epidemiology, real-world evidence, safety and risk management.

The new unit will retain the Evidera name and will be led by Williams.

Executive and scientific leadership of both Evidera and the medical affairs research operations organizations will also remain in place.

Related news

Show more

Related products

show more

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers